-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, R5BYZufd9kmytdsByqIx6zUpnVEVVeWewRdViEKTkJ3rD5Mpvh3dsQquOsqq2oW7 2eJs+01elNNpNK8wbWKDVQ== 0001144204-09-040489.txt : 20090805 0001144204-09-040489.hdr.sgml : 20090805 20090805121246 ACCESSION NUMBER: 0001144204-09-040489 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090805 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090805 DATE AS OF CHANGE: 20090805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Yongye Biotechnology International, Inc. CENTRAL INDEX KEY: 0001398551 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 208051010 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-143314 FILM NUMBER: 09986239 BUSINESS ADDRESS: STREET 1: 3195 UPPER LEVEL RD. #182 CITY: ROBSON STATE: A1 ZIP: VOG 1XO BUSINESS PHONE: 604-720-4393 MAIL ADDRESS: STREET 1: 3195 UPPER LEVEL RD. #182 CITY: ROBSON STATE: A1 ZIP: VOG 1XO FORMER COMPANY: FORMER CONFORMED NAME: Golden Tan, Inc DATE OF NAME CHANGE: 20070504 8-K 1 v156238_8k.htm FORM 8-K


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (date of earliest event reported): August 5, 2009

YONGYE INTERNATIONAL, INC.
(Exact name of Registrant as Specified in Charter)

Nevada
 
333-143314
20-8051010
(State of Incorporation)
 (Commission File No.)
(IRS Employer
Identification No.)
 

6th Floor, Suite 608, Xue Yuan International Tower,
No. 1 Zhichun Road, Haidian District, Beijing, PRC

(Address Of Principal Executive Offices) (Zip Code)
 
+86 10 8231 8626
(Registrant’s Telephone Number, Including Area Code)

Yongye Biotechnology International, Inc. 

(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
r
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
r
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 
r
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
r
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 



 
 
                     
Item 8.01
Other Events.
 
On April 20, 2009, the board of directors of Yongye International, Inc. adopted a Code of Ethics.
 
 
Item 9.01
Financial Statements and Exhibits
 
(d)
Exhibit No.
Description
     
 
14.1
Code of Ethics
 
                                       
 
                                                    
 

 

2


 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
  YONGYE INTERNATIONAL, INC.
     
       
Dated: August 5, 2009
By:
/s/ Zishen Wu  
    Name: Zishen Wu  
    Title:   President and CEO  
       
 
 
 
3

EX-14.1 2 v156238_ex14-1.htm CODE OF ETHICS

CODE OF ETHICS OF
YONGYE BIOTECHNOLOGY INTERNATIONAL, INC.
APPLICABLE TO DIRECTORS, OFFICERS AND EMPLOYEES

YONGYE BIOTECHNOLOGY INTERNATIONAL, INC.道德规范准则
(适用于董事、高级管理人员及职员)

To promote the ethical conduct and integrity generally of Yongye Biotechnology International, Inc. (the “Company”), and to promote accurate, fair and timely reporting of the Company's financial results and condition and other information we release to the public market and include in reports we file with the Securities and Exchange Commission (the “SEC”), all directors, officers and employees of the company are bound by the following Code of Ethics, under which each agrees that he or she shall:
为从总的方面提高Yongye Biotechnology International, Inc. (以下简称“公司”)的道德行为和诚信度,提高公司向公众市场发布以及向证券交易委员会(“SEC”)提交的公司财务结果和营运状况和其他信息的精确性、公正性和及时性,公司的全体董事、高级管理人员及职员受到如下道德规范准则的约束,每È 10;人均同意:

·  
Act with honesty and integrity, avoiding actual or apparent conflicts of interest in personal and professional relationships, including disclosure to the Chairman of the Audit Committee of any material transaction or relationship that reasonably could be expected to give rise to such a conflict.
诚实正直地行为,避免个人与职业之间发生实际或明显的利益冲突,包括向审计委员会主席披露可能会引起此种利益冲突的重大交易或关系。

·  
Be prohibited from: personally taking advantage of business opportunities that are discovered through the use of corporate property, information or his or her position with the company; using corporate property, information or his or her position for personal gain; or competing against the company while an employee.
禁止:个人利用在公司的财产、信息使用中、或本人在公司的职位上发现的商业机会;
利用公司财产、信息、或本人在公司的职位来谋求个人利益;或在公司担任职员期间与公司竞争。

·  
Provide information within the scope of his or her duties in a manner which promotes full, fair, accurate, timely and understandable disclosure in reports and documents that the company files with, or submits to, government agencies and in the company's other public communications.
在工作职责范围内以一定的方式提供信息,以提高公司向政府机构提交或公司向公众呈现的报告和文件中内容的完整性、公正性、准确性、及时性和易理解性。
 
 
 

 

 
·  
Comply with rules and regulations of foreign, federal, state, provincial and local governments, and other appropriate private and public regulatory agencies, including insider trading laws.
遵守外国、联邦、州、省、地方政府及其他的适当的私立或政府管理机构的法律、法规和规定,包括内幕交易法。

·  
Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing one's independent judgment to be subordinated.
行为诚信、负责、认真、胜任、勤勉,不曲解重要的事实或是允许自己的独立判断服从他人意见。

·  
Deal fairly with the company’s customers, suppliers, competitors and employees, and not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any other unfair dealings.
公平对待公司的客户、供应商、竞争对手和职员,不通过操纵、隐瞒、滥用特许信息、虚报重要的事实或者任何其他不公平的交易的手段而对他人不正当地利用。

遵守对个人工作中获得的资料的保密义务, 除非获得批准或有法律义务进行公开。不得利用在工作中获得的机密资料谋求个人利益。

·  
Proactively promote and be an example of ethical behavior.
积极努力,成为遵守道德规范的表率。

·  
Achieve responsible use of and control over all assets and resources employed or entrusted.
对所使用或看管的所有资产和物资有责任心。

·  
Promptly report to the Chairman of the Audit Committee any conduct that the individual believes to be or would give rise to a violation of law or business ethics or of any provision of this Code of Ethics or the Company's general code of conduct. 
如发现任何可导致违法、违背商业道德、违背这一道德规范或是违背公司一般行为守则的行为,迅速向审计委员会主席汇报。

 
2

 
It is against the company's policy to retaliate against any employee for good faith reporting of violations of this Code.  Violations of this Code of Ethics, including failures to report potential violations by others, will be viewed as a severe disciplinary matter that may result in personnel action, including termination of employment.  Any waiver of this Code for executive officers or directors may be made only by the board of directors or an authorized committee of the board of directors and must be promptly disclosed to stockholders.
对举报不良行为的员工进行报复将违反公司的政策。违反本道德规范,包括未能举报他人的不良行为,将被视为严重违纪,人事部门将予以处罚,甚至开除。只能由董事局或董事局授权的委员会对执行官或董事决定豁免适用本规范,但必须& #36805;速通报给股东。

If you believe that a violation of the Code of Ethics has occurred, please contact the Chairman of the Audit Committee.
如果你认为发生了违反道德规范的事件,请与审计委员会主席联系。


DatedApril 20, 2009
日期: 20094__
 
 

 
 
3

 

-----END PRIVACY-ENHANCED MESSAGE-----